EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial

Tae Hyeon Kim, Kyeongmin Lee, Jaehyeong Cho, Jiyeon Oh, Sooji Lee, Lee Smith, Francesco Branda iD, Junyang Jung, Jinseok Lee, Hayeon Lee, Dong Keon Yon iD

Allergy · 2026

DOI: 10.1111/all.70056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2026. Verfasst von Tae Hyeon Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, …. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Herpes Zoster. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent previous study suggests that live zoster vaccination may reduce the risk of diseases like dementia and cardiovascular diseases, through prevention of herpes zoster. Thus, this study aims to evaluate whether live zoster vaccination can reduce the risk of chronic respiratory disease including chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung disease (ILD).

Methods

This target trial emulation study utilized a nationwide, population‐based cohort of 2,519,582 individuals aged ≥ 50 years in South Korea. The cohort was constructed by integrating health insurance data from the Korea Health Insurance Review and Assessment Service, national health examination data from the Korean National Health Insurance Service, and vaccination records from the Korea Disease Control and Prevention Agency. The exposure was receipt of at least one dose of live zoster vaccination between January 1, 2012, and December 31, 2021. Outcomes included the incidence of newly diagnosed COPD, asthma, and ILD, as well as hospitalizations associated with these conditions. Following stabilized inverse probability of treatment weighting, we employed the Cox proportional hazards model to estimate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) and calculated restricted mean survival time (RMST) for the risk of outcomes associated with live zoster vaccination. The observation period extends from the index date to January 31, 2024. Measurements and Main Results After stabilized inverse probability of treatment weighting, 745,644 individuals were assigned to the vaccinated group and 1,069,230 to the unvaccinated group, with a mean age of 62.12 years (SD, 3.45) and 49.18% were male. Live zoster vaccination significantly reduced the risk of COPD (aHR, 0.70 [95% CI, 0.69–0.71]; RMST difference, 23.22 days [95% CI, 21.72–24.71]), asthma (0.68 [0.67–0.69]; 25.96 days [24.52–27.40]) and ILD (0.78 [0.73–0.82]; 2.39 days [2.05–2.74]). Additionally, the vaccination significantly reduced the risk of hospital admissions due to these conditions: COPD (0.59 [0.53–0.65]), asthma (0.54 [0.49–0.59]), and ILD (0.68 [0.58–0.79]). The observed protective benefit was more pronounced in non‐smokers compared to current smokers. The time‐attenuated effect was strongest during 1 to 2 years following live zoster vaccination and remained evident for up to 6 years.

Conclusions

Live zoster vaccination significantly reduced the incidence of chronic respiratory disease and related hospitalizations. These findings suggest that live zoster vaccination may provide public health benefits beyond preventing herpes zoster in adults aged ≥ 50 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes Zoster VaccineHerpes ZosterHumansMaleFemaleMiddle AgedAgedRepublic of KoreaVaccinationIncidenceChronic DiseasePulmonary Disease, Chronic ObstructiveAged, 80 and overRisk FactorsProportional Hazards ModelsCohort Studies

Stichwörter der Autor:innen

asthmachronic obstructive pulmonary diseasechronic respiratory diseaseherpes zosterinterstitial lung diseaselive zoster vaccination

Substanzen

Herpes Zoster Vaccine

Autor:innen und Institutionen

  • Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
  • Department of Medicine, CHA University School of Medicine, Seongnam, South Korea.
  • Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
  • Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.

ORCID-Profile: Francesco Branda, Dong Keon Yon

Förderung

  • Ministry of Science and ICT, South Korea

Zitieren

APA

Kim, T. H., Lee, K., Cho, J., Oh, J., Lee, S., Smith, L., Branda, F., Jung, J., Lee, J., Lee, H., & Yon, D. K. (2026). Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial. Allergy. https://doi.org/10.1111/all.70056

Vancouver

Kim TH, Lee K, Cho J, Oh J, Lee S, Smith L, et al. Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial. Allergy. 2026. doi:10.1111/all.70056

BibTeX
@article{Kim2026,
  author = {Kim, Tae Hyeon and Lee, Kyeongmin and Cho, Jaehyeong and Oh, Jiyeon and Lee, Sooji and Smith, Lee and Branda, Francesco and Jung, Junyang and Lee, Jinseok and Lee, Hayeon and Yon, Dong Keon},
  title = {Live Zoster Vaccination and the Reduced Risk of Chronic Respiratory Diseases: An Emulated Target Trial},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70056}
}
Kostenlos starten →